Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib neoadjuvant therapy in advanced ovarian cancer
NCT06541314Phase 2Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Jun 2024
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluzoparib in ovarian cancer, sponsored by Qilu Hospital of Shandong University. Primary endpoints: Objective Response Rate at 10 weeks and R0 Resection Rate. Started Jun 2024; status: recruiting.
02
Drugs
fluzoparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT06541314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06541314.